Jonathan Poole

Vertex Pharmaceuticals has split the operating and finance responsibilities held by Charles Wagner as it begins integrating the $10 billion Crinetics Pharmaceuticals acquisition and targets more than $5 billion of potential peak sales from its new endocrine assets.